Clinical Trial Update: Deferoxamine Plus Chemotherapy for Metastatic Triple Negative Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating deferoxamine in combination with chemotherapy for metastatic triple-negative breast cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• Chemotherapy (unspecified)
• Deferoxamine (deferoxamine)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Triple Negative Breast Cancer | Phase 2 | Status: TERMINATED